Hematopoietic stem cell transplantation for people with sickle cell disease.
Journal
The Cochrane database of systematic reviews
ISSN: 1469-493X
Titre abrégé: Cochrane Database Syst Rev
Pays: England
ID NLM: 100909747
Informations de publication
Date de publication:
03 07 2020
03 07 2020
Historique:
entrez:
4
7
2020
pubmed:
4
7
2020
medline:
20
9
2020
Statut:
epublish
Résumé
Sickle cell disease is a genetic disorder involving a defect in the red blood cells due to its sickled hemoglobin. The main therapeutic interventions include preventive and supportive measures. Hematopoietic stem cell transplantations are carried out with the aim of replacing the defective cells and their progenitors (hematopoietic (i.e. blood forming) stem cells) in order to correct the disorder. This is an update of a previously published review. To determine whether stem cell transplantation can improve survival and prevent symptoms and complications associated with sickle cell disease. To examine the risks of stem cell transplantation against the potential long-term gain for people with sickle cell disease. We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Group's Haemoglobinopathies Trials Register complied from electronic searches of the Cochrane Central Register of Controlled Trials (CENTRAL) (updated each new issue of the Cochrane Library) and quarterly searches of MEDLINE. We also searched trial registries for ongoing trials up to April 2020. Date of the most recent search of the Group's Haemoglobinopathies Trials Register: 09 December 2019. Randomized controlled and quasi-randomized trials that compared any method of stem cell transplantation with either each other or with any of the preventive or supportive interventions (e.g. periodic blood transfusion, use of hydroxyurea, antibiotics, pain relievers, supplemental oxygen) in people with sickle cell disease irrespective of the type of sickle cell disease, gender and setting. No trials were eligible for inclusion in the review. We identified 12 potentially-eligible trials by the searches; we excluded 11 of these and the remaining trial is an ongoing trial that may be eligible for inclusion in a future version of the review. Reports on the use of hematopoietic stem cell transplantation improving survival and preventing symptoms and complications associated with sickle cell disease are currently limited to observational and other less robust studies. We did not find any eligible randomized controlled trials assessing the benefit or risk of hematopoietic stem cell transplantations. However, there is an ongoing quasi-randomized trial comparing hematopoietic stem cell transplantation with standard care, Thus, this systematic review identifies the need for a multicentre randomized controlled trial assessing the benefits and possible risks of hematopoietic stem cell transplantations comparing sickle status and severity of disease in people with sickle cell disease.
Sections du résumé
BACKGROUND
Sickle cell disease is a genetic disorder involving a defect in the red blood cells due to its sickled hemoglobin. The main therapeutic interventions include preventive and supportive measures. Hematopoietic stem cell transplantations are carried out with the aim of replacing the defective cells and their progenitors (hematopoietic (i.e. blood forming) stem cells) in order to correct the disorder. This is an update of a previously published review.
OBJECTIVES
To determine whether stem cell transplantation can improve survival and prevent symptoms and complications associated with sickle cell disease. To examine the risks of stem cell transplantation against the potential long-term gain for people with sickle cell disease.
SEARCH METHODS
We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Group's Haemoglobinopathies Trials Register complied from electronic searches of the Cochrane Central Register of Controlled Trials (CENTRAL) (updated each new issue of the Cochrane Library) and quarterly searches of MEDLINE. We also searched trial registries for ongoing trials up to April 2020. Date of the most recent search of the Group's Haemoglobinopathies Trials Register: 09 December 2019.
SELECTION CRITERIA
Randomized controlled and quasi-randomized trials that compared any method of stem cell transplantation with either each other or with any of the preventive or supportive interventions (e.g. periodic blood transfusion, use of hydroxyurea, antibiotics, pain relievers, supplemental oxygen) in people with sickle cell disease irrespective of the type of sickle cell disease, gender and setting.
DATA COLLECTION AND ANALYSIS
No trials were eligible for inclusion in the review.
MAIN RESULTS
We identified 12 potentially-eligible trials by the searches; we excluded 11 of these and the remaining trial is an ongoing trial that may be eligible for inclusion in a future version of the review.
AUTHORS' CONCLUSIONS
Reports on the use of hematopoietic stem cell transplantation improving survival and preventing symptoms and complications associated with sickle cell disease are currently limited to observational and other less robust studies. We did not find any eligible randomized controlled trials assessing the benefit or risk of hematopoietic stem cell transplantations. However, there is an ongoing quasi-randomized trial comparing hematopoietic stem cell transplantation with standard care, Thus, this systematic review identifies the need for a multicentre randomized controlled trial assessing the benefits and possible risks of hematopoietic stem cell transplantations comparing sickle status and severity of disease in people with sickle cell disease.
Identifiants
pubmed: 32617981
doi: 10.1002/14651858.CD007001.pub5
pmc: PMC7390490
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
CD007001Commentaires et corrections
Type : UpdateOf
Informations de copyright
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Références
Expert Opin Biol Ther. 2003 Dec;3(8):1215-24
pubmed: 14640947
Ther Adv Hematol. 2013 Oct;4(5):335-44
pubmed: 24082994
Bone Marrow Transplant. 1998 Jul;22(1):1-6
pubmed: 9678788
Lancet. 1988 Aug 6;2(8606):328-9
pubmed: 2899733
Bone Marrow Transplant. 2004 Sep;34(5):405-11
pubmed: 15247929
BMJ. 1997 Sep 13;315(7109):629-34
pubmed: 9310563
Am J Hematol. 2014 May;89(5):530-5
pubmed: 24478166
Bone Marrow Transplant. 1993;12 Suppl 1:122-3
pubmed: 8374552
Lancet. 2010 Dec 11;376(9757):2018-31
pubmed: 21131035
Blood. 2016 Nov 24;128(21):2561-2567
pubmed: 27625358
N Engl J Med. 1998 Jul 2;339(1):5-11
pubmed: 9647873
Blood Rev. 2003 Sep;17(3):163-6
pubmed: 12818226
Blood. 2000 May 15;95(10):3057-64
pubmed: 10807769
Bone Marrow Transplant. 2004 Feb;33(4):377-9
pubmed: 14676781
Control Clin Trials. 1986 Sep;7(3):177-88
pubmed: 3802833
Cochrane Database Syst Rev. 2017 Apr 20;4:CD002202
pubmed: 28426137
Pediatrics. 1988 Jun;81(6):749-55
pubmed: 3368274
Bone Marrow Transplant. 2000 Aug;26(4):445-9
pubmed: 10982293
Blood. 2003 Mar 15;101(6):2137-43
pubmed: 12424197
Biol Blood Marrow Transplant. 2003 Aug;9(8):519-28
pubmed: 12931121
JAMA. 2003 Apr 2;289(13):1645-51
pubmed: 12672732
Cochrane Database Syst Rev. 2016 May 19;(5):CD007001
pubmed: 27194464
Am J Hematol. 2010 Jun;85(6):403-8
pubmed: 20513116
J Pediatr. 1996 Feb;128(2):241-3
pubmed: 8636820
Stroke. 1992 Aug;23(8):1073-7
pubmed: 1636180
Lancet. 2017 Jul 15;390(10091):311-323
pubmed: 28159390
Blood. 2017 Mar 16;129(11):1548-1556
pubmed: 27965196
Pediatr Blood Cancer. 2012 Aug;59(2):386-90
pubmed: 22535620
Blood. 1995 Feb 15;85(4):879-84
pubmed: 7849310
N Engl J Med. 1994 Jun 9;330(23):1639-44
pubmed: 7993409
Cochrane Database Syst Rev. 2013 May 31;(5):CD007001
pubmed: 23728664
J Blood Med. 2015 Jul 10;6:229-38
pubmed: 26203293
N Engl J Med. 1984 Sep 20;311(12):780-3
pubmed: 6382010
Bone Marrow Transplant. 2005 Jan;35(2):171-7
pubmed: 15531901
N Engl J Med. 1986 Jun 19;314(25):1593-9
pubmed: 3086721
Semin Hematol. 1991 Jul;28(3):250-9
pubmed: 1887253
Br J Haematol. 2007 Jun;137(5):479-85
pubmed: 17459050
Blood. 2001 Mar 1;97(5):1458-66
pubmed: 11222394
PLoS Med. 2013;10(7):e1001484
pubmed: 23874164
N Engl J Med. 1996 Aug 8;335(6):369-76
pubmed: 8663884
Blood. 1999 Feb 15;93(4):1164-7
pubmed: 9949158
Blood. 2007 Oct 1;110(7):2749-56
pubmed: 17606762
J Pediatr. 2009 Apr;154(4):541-5
pubmed: 19028391
Blood. 2000 Mar 15;95(6):1918-24
pubmed: 10706855
Biol Blood Marrow Transplant. 2001;7(12):665-73
pubmed: 11787529
Bone Marrow Transplant. 1993;12 Suppl 1:118-21
pubmed: 8374551
Cochrane Database Syst Rev. 2009 Jan 21;(1):CD007001
pubmed: 19160312
Lancet. 2004 Jul 10-16;364(9429):156-62
pubmed: 15246728
Biol Blood Marrow Transplant. 2005 May;11(5):349-53
pubmed: 15846288